Clearside Biomedical, Inc.

📍 Alpharetta, United States🗓 Founded 2012👥 40 employees💰 Last funded Aug 2014
Biotechnology Research🌐 clearsidebio.com
Website LinkedIn
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE™ (triamcinolone acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration in October 2021.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2012
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Clearside Biomedical, Inc.?
Clearside Biomedical, Inc. has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Clearside Biomedical, Inc. last raise funding?
The most recent investment in Clearside Biomedical, Inc. recorded on gritt.io was in August 2014.
When was Clearside Biomedical, Inc. founded?
Clearside Biomedical, Inc. was founded in 2012.
What industry is Clearside Biomedical, Inc. in?
Clearside Biomedical, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Clearside Biomedical, Inc. based?
Clearside Biomedical, Inc. is headquartered in Alpharetta, United States.